Published in Clin Cancer Res on August 15, 2005
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol (2008) 2.79
Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood (2009) 2.39
NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol (2013) 2.39
Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat. J Neuroinflammation (2016) 1.38
Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica (2009) 1.38
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol (2011) 1.26
Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol (2011) 1.08
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J (2013) 1.01
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Front Immunol (2014) 1.00
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol (2010) 0.99
Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol (2007) 0.97
Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica (2013) 0.94
Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma. J Clin Oncol (2015) 0.94
Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One (2013) 0.93
Beyond high-dose methotrexate and brain radiotherapy: novel targets and agents for primary CNS lymphoma. Ann Oncol (2013) 0.93
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma (2010) 0.92
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev (2016) 0.91
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol Immunother (2013) 0.89
Novel immune modulators used in hematology: impact on NK cells. Front Immunol (2013) 0.89
Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy. J Hematol Oncol (2013) 0.89
Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells. Biomed Res Int (2014) 0.86
Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol Immunother (2013) 0.86
Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. PLoS One (2013) 0.85
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood (2015) 0.82
Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. Ther Adv Hematol (2013) 0.81
Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs (2012) 0.80
Lenalidomide in diffuse large B-cell lymphomas. Adv Hematol (2012) 0.79
Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol (2014) 0.78
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies. Invest New Drugs (2016) 0.76
Immunomodulatory activity of orphan drug Elmiron® in female B6C3F1/N mice. Food Chem Toxicol (2014) 0.76
Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol (2012) 0.76
Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option? Oncologist (2016) 0.75
Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. Oncotarget (2017) 0.75
The emerging role of lenalidomide in the management of lymphoid malignancies. Ther Adv Hematol (2011) 0.75
Increased serum tumor necrosis factor α levels in patients with lenalidomide-induced hypothyroidism. Exp Hematol (2014) 0.75
Potential for a novel manganese porphyrin compound as adjuvant canine lymphoma therapy. Cancer Chemother Pharmacol (2017) 0.75
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer (2010) 2.19
Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res (2003) 2.09
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park) (2009) 2.06
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol (2007) 2.05
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer (2011) 1.92
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer (2010) 1.90
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma (2010) 1.78
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma (2012) 1.62
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (2013) 1.60
Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leuk Lymphoma (2012) 1.41
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol (2010) 1.38
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood (2008) 1.30
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 1.26
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol (2011) 1.26
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest (2006) 1.20
Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw (2013) 1.20
Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw (2014) 1.17
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol (2012) 1.17
Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res (2008) 1.16
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol (2008) 1.15
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood (2012) 1.08
Non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2011) 1.06
Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol (2011) 1.04
Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Netw (2012) 1.03
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer (2011) 0.97
Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res (2007) 0.95
Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw (2014) 0.94
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res (2008) 0.93
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer (2013) 0.90
Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol (2004) 0.90
Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res (2012) 0.89
Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma (2005) 0.89
Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control (2005) 0.89
Diffuse Large B-Cell Lymphoma Version 1.2016. J Natl Compr Canc Netw (2016) 0.89
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol (2011) 0.88
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol (2013) 0.88
Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol (2004) 0.88
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr Opin Investig Drugs (2009) 0.88
Non-Hodgkin's lymphoma presenting as a breast mass in patients with HIV infection: a report of three cases. Leuk Lymphoma (2005) 0.87
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma (2009) 0.87
Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leuk Lymphoma (2004) 0.87
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leuk Lymphoma (2014) 0.87
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res (2013) 0.86
T-cell clonality and myelodysplasia without chromosomal fragility in a patient with features of Seckel syndrome. Haematologica (2003) 0.85
Bortezomib for the treatment of non-Hodgkin's lymphoma. Expert Opin Pharmacother (2014) 0.85
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park) (2009) 0.84
Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunol Res (2010) 0.84
Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood (2010) 0.83
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer (2014) 0.82
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol (2015) 0.82
Antibody-drug conjugate technology development for hematologic disorders. Clin Adv Hematol Oncol (2012) 0.82
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.82
Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer (2006) 0.81
Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Health Syst Pharm (2010) 0.81
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol (2013) 0.81
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation. Leuk Lymphoma (2008) 0.81
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw (2015) 0.81
Advances and application of radioimmunotherapy in non-Hodgkin lymphoma. Am J Blood Res (2012) 0.80
The use of galiximab in non-Hodgkin lymphoma. Clin Lymphoma Myeloma (2008) 0.80
Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage. Leuk Lymphoma (2007) 0.80
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol (2013) 0.80
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma (2004) 0.79
Brentuximab in the treatment of CD30-positive enteropathy-associated T-cell lymphoma. J Natl Compr Canc Netw (2013) 0.79
Immunomodulatory nonablative conditioning regimen for B-cell lymphoid malignancies. Exp Hematol (2012) 0.79
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol (2011) 0.79
NCCN task force report: molecular markers in leukemias and lymphomas. J Natl Compr Canc Netw (2009) 0.79
Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma. Clin Adv Hematol Oncol (2004) 0.79
High Prevalence of Obesity in Acute Promyelocytic Leukemia (APL): Implications for Differentiating Agents in APL and Metabolic Syndrome. Ther Adv Hematol (2011) 0.78
Galiximab: a review. Expert Opin Biol Ther (2010) 0.78
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer (2014) 0.78
Non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2008) 0.78
Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies. Expert Rev Hematol (2011) 0.78
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models. Anticancer Drugs (2013) 0.77
Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future Oncol (2011) 0.77
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol (2002) 0.77
Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncol (2013) 0.76
Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion. Transplantation (2004) 0.76
Prophylactic intravenous immunoglobulin does not have a role in hematopoietic stem-cell transplantation: is the evidence clear? J Clin Oncol (2009) 0.75
Review: erythroleukemia: clinical course and management. Clin Adv Hematol Oncol (2010) 0.75
Does extra alemtuzumab remove the graft-versus-leukemia effect after allogeneic stem cell transplantation in chronic lymphocytic leukemia? Biol Blood Marrow Transplant (2009) 0.75
Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells. Oncotarget (2016) 0.75
Integrating emerging treatment options in mantle cell lymphoma. Clin Adv Hematol Oncol (2013) 0.75
Amyloidosis: A rare disease with varied manifestations. Curr Probl Cancer (2016) 0.75
Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAART. HIV Clin Trials (2004) 0.75